How Common Is DCIS, and Can Men Develop It? Key Facts
At a Glance
DCIS is common among breast cancers found in women through mammography, but it is very rare in men. It stays inside the milk ducts, though some cases can become invasive, so biopsy results and individual risk factors guide treatment and genetic counseling.
In this answer
4 sections
Ductal carcinoma in situ (DCIS) is noninvasive, meaning the abnormal cells are confined to the milk ducts and cannot spread to other parts of the body unless an invasive component develops or was missed during biopsy. The prognosis is generally excellent, but because of its potential to become invasive over time, it requires careful evaluation.
Incidence and Age Trends
DCIS is frequently found during breast imaging in women. It accounts for roughly 15% to 25% of all newly diagnosed breast cancers in the United States [1][2]. Men can also develop DCIS, but it is exceptionally rare; pure DCIS accounts for only about 5% to 10% of all male breast cancer cases [3][4].
In U.S. data, such as the SEER registry from 2000 to 2014, the average age at the time of a DCIS diagnosis was typically in the mid-to-late 50s [5][6]. While overall rates of diagnosis remained broadly stable during that period, there was a slight annual increase in diagnoses among younger women between the ages of 20 and 55 [6].
The Impact of Mammography Screening
The high number of DCIS cases diagnosed today is primarily the result of widespread mammography screening [7]. Mammograms are highly effective at spotting microcalcifications—tiny deposits of calcium in the breast tissue [8]. It is important to know that many calcifications are completely benign (harmless), but they can indicate an area that needs additional imaging and a biopsy. A mammogram cannot diagnose DCIS; only a biopsy examined by a pathologist can confirm the diagnosis.
Because modern screening catches so many early lesions, experts acknowledge that some cases of DCIS represent overdiagnosis [9]. Overdiagnosis means that a detected DCIS would never have grown, spread, or caused symptoms during the person’s natural lifetime [10]. However, doctors currently cannot predict with absolute certainty which individual cases of DCIS will remain harmless and which will progress to invasive cancer [9].
While most medical guidelines favor definitive treatment (such as surgery, sometimes followed by radiation or hormone-blocking therapy) to reduce the risk of a future invasive recurrence, management is highly individualized [10][11]. Doctors look at features like tumor grade (how abnormal the cells look) and hormone receptor status (whether the cells grow in response to estrogen or progesterone) to guide care [12][11]. For some selected patients with low-risk features, active surveillance (careful monitoring) may be discussed, often as part of a clinical trial [10].
Racial and Ethnic Patterns
When looking at populations, diagnosis rates and outcomes can vary. Over recent decades, U.S. registry data showed increasing DCIS diagnoses among Black, Hispanic, and Asian/Pacific Islander women [13]. However, when researchers adjusted the data to account for differences in mammography screening rates, the underlying incidence of DCIS was very similar between Black and White women [13].
Despite similar underlying rates, disparities exist in disease outcomes. Some data indicate that Black women may face a higher risk of DCIS returning as an invasive cancer or have a higher breast cancer-specific mortality rate compared to White women [14][15]. These differences are complex and are influenced by healthcare access, treatment delays, socioeconomic factors, and tumor biology [16][11].
DCIS in Men and Genetic Risk
Men have a small amount of breast tissue containing milk ducts, meaning they can develop DCIS [3]. American Society of Clinical Oncology (ASCO) guidelines state that genetic counseling and inherited (germline) genetic testing should be offered to all men diagnosed with breast cancer, including DCIS, regardless of their age or family history [17][18].
Genetic evaluation is particularly crucial if a man has a family history of:
- Male breast cancer [19]
- Female breast cancer diagnosed before age 50 [20]
- Ovarian, pancreatic, or aggressive prostate cancer [20][21]
Testing usually involves a multigene panel (testing multiple genes at once, such as BRCA1, BRCA2, PALB2, and CHEK2) [22][23]. It is important to know that a genetic test can be negative, and a DCIS diagnosis does not mean a genetic mutation is inevitable. Sometimes tests reveal a “variant of uncertain significance,” which should not be used to guide preventive care [17].
However, if a clinically significant mutation is found, it can help guide the patient’s own future screenings (like for prostate or pancreatic cancer, depending on the exact gene involved) [24]. It also allows blood relatives to receive cascade testing (targeted testing for that specific family mutation) after they undergo their own genetic counseling [17].
Common questions in this guide
How common is ductal carcinoma in situ?
Can men develop DCIS?
How is DCIS confirmed after a mammogram?
Does a DCIS diagnosis mean the cancer is invasive?
Should a man with DCIS have genetic testing?
Can DCIS be overdiagnosed?
Related questions
Get notified when new evidence is published on ductal breast carcinoma in situ.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (24)
- 1
Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment.
Delaloge S, Khan SA, Wesseling J, Whelan T
Lancet (London, England) 2024; (403(10445)):2734-2746 doi:10.1016/S0140-6736(24)00425-2.
PMID: 38735296 - 2
Intratumoral Heterogeneity in Ductal Carcinoma In Situ: Chaos and Consequence.
Sinha VC, Piwnica-Worms H
Journal of mammary gland biology and neoplasia 2018; (23(4)):191-205 doi:10.1007/s10911-018-9410-6.
PMID: 30194658 - 3
Male ductal carcinoma in situ: diagnosis and management of a rare disease in men.
Tian C, Alvarado R, Kim T, Slostad J
BMJ case reports 2024; (17(3)) doi:10.1136/bcr-2023-256608.
PMID: 38499353 - 4
Mammographically and sonographically occult male DCIS seen only on breast MRI.
Osei K, Panigrahi B
Radiology case reports 2024; (19(8)):3390-3393 doi:10.1016/j.radcr.2024.05.006.
PMID: 38841603 - 5
Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.
Narod SA, Iqbal J, Giannakeas V, et al.
JAMA oncology 2015; (1(7)):888-96 doi:10.1001/jamaoncol.2015.2510.
PMID: 26291673 - 6
Incidence of Ductal Carcinoma In Situ in the United States, 2000-2014.
Ryser MD, Hendrix LH, Worni M, et al.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2019; (28(8)):1316-1323 doi:10.1158/1055-9965.EPI-18-1262.
PMID: 31186262 - 7
The contribution of mammography screening to breast cancer incidence trends in the United States: an updated age-period-cohort model.
Gangnon RE, Sprague BL, Stout NK, et al.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2015; (24(6)):905-12 doi:10.1158/1055-9965.EPI-14-1286.
PMID: 25787716 - 8
Recall and Outcome of Screen-detected Microcalcifications during 2 Decades of Mammography Screening in the Netherlands National Breast Screening Program.
Luiten JD, Voogd AC, Luiten EJT, et al.
Radiology 2020; (294(3)):528-537 doi:10.1148/radiol.2020191266.
PMID: 31990268 - 9
Overdiagnosis of ductal carcinoma in situ by grade and definition in population-based screening: A modeling study.
Poelhekken K, Greuter MJW, van der Vegt B, et al.
Breast (Edinburgh, Scotland) 2025; (84()):104594 doi:10.1016/j.breast.2025.104594.
PMID: 41082841 - 10
Modeling Ductal Carcinoma In Situ (DCIS): An Overview of CISNET Model Approaches.
van Ravesteyn NT, van den Broek JJ, Li X, et al.
Medical decision making : an international journal of the Society for Medical Decision Making 2018; (38(1_suppl)):126S-139S doi:10.1177/0272989X17729358.
PMID: 29554463 - 11
Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial.
Kantor O, King TA, Jones A, et al.
Annals of surgical oncology 2023; (30(13)):8404-8411 doi:10.1245/s10434-023-14344-z.
PMID: 37777685 - 12
Racial Disparity in Ductal Carcinoma in Situ: Risk-Predictive and Actionable Biomarkers for Early Intervention.
Franklin D, Rida P, Jinna N
Cancers 2026; (18(11)) doi:10.3390/cancers18111794.
PMID: 42279376 - 13
Twenty-Five Year Trends in the Incidence of Ductal Carcinoma in Situ in US Women.
Oseni TO, Zhang B, Coopey SB, et al.
Journal of the American College of Surgeons 2019; (228(6)):932-939 doi:10.1016/j.jamcollsurg.2019.01.018.
PMID: 30772444 - 14
Race-related subsequent breast events after ductal carcinoma in situ: A Surveillance, Epidemiology, and End Results-based analysis.
Koric A, Jiang S, Liu Y, Colditz GA
Cancer 2025; (131(22)):e70164 doi:10.1002/cncr.70164.
PMID: 41199479 - 15
Trends in breast cancer death rates from ductal carcinoma in situ versus invasive cancer in the United States.
Sung H, Jiang C, Jatoi I, Jemal A
Breast cancer research : BCR 2025; (27(1)):164 doi:10.1186/s13058-025-02068-9.
PMID: 41013593 - 16
Racial/ethnic differences in tumor biology and treatment outcomes in women with ductal carcinoma in situ.
Black DM, Day CN, Piltin MA, et al.
Surgery 2025; (179()):108940 doi:10.1016/j.surg.2024.08.059.
PMID: 39603875 - 17
Management of Male Breast Cancer: ASCO Guideline.
Hassett MJ, Somerfield MR, Baker ER, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(16)):1849-1863 doi:10.1200/JCO.19.03120.
PMID: 32058842 - 18
Multigene Germline Testing in Patients with DCIS vs Invasive Breast Cancer in a Large, Integrated Health Care System.
Dzubnar JM, Habel LA, Jiang SF, et al.
Annals of surgical oncology 2026; (33(5)):4436-4442 doi:10.1245/s10434-025-19053-3.
PMID: 41530599 - 19
Family history of breast cancer in men with non-BRCA male breast cancer: implications for cancer risk counseling.
Calip GS, Kidd J, Bernhisel R, et al.
Breast cancer research and treatment 2021; (185(1)):195-204 doi:10.1007/s10549-020-05922-w.
PMID: 32918117 - 20
Protocol to evaluate sequential electronic health record-based strategies to increase genetic testing for breast and ovarian cancer risk across diverse patient populations in gynecology practices.
Symecko H, Schnoll R, Beidas RS, et al.
Implementation science : IS 2023; (18(1)):57 doi:10.1186/s13012-023-01308-w.
PMID: 37932730 - 21
Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers.
Clark NM, Roberts EA, Fedorenko C, et al.
Annals of surgical oncology 2023; (30(3)):1312-1326 doi:10.1245/s10434-022-12755-y.
PMID: 36335273 - 22
Prevalence of Cancer Predisposition Germline Variants in Male Breast Cancer Patients: Results of the German Consortium for Hereditary Breast and Ovarian Cancer.
Rolfes M, Borde J, Möllenhoff K, et al.
Cancers 2022; (14(13)) doi:10.3390/cancers14133292.
PMID: 35805063 - 23
Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.
Pritzlaff M, Summerour P, McFarland R, et al.
Breast cancer research and treatment 2017; (161(3)):575-586 doi:10.1007/s10549-016-4085-4.
PMID: 28008555 - 24
Cancer risks associated with BRCA1 and BRCA2: Overview and management.
Breen KE, Vashisth S, Liu YL
Cancer 2026; (132(20)):e70635 doi:10.1002/cncr.70635.
PMID: 42875977
This page is for informational purposes only and does not constitute medical advice about DCIS, male breast cancer, or genetic testing. Discuss your individual diagnosis and options with your healthcare team.